Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often sold as Zepbound, and semaglutide, often sold as Wegovy, over.

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular weight-loss med at $499 per month. | Novo Nordisk has quickly expanded its discounted Wegovy program,